Your shopping cart is currently empty

(R)-Terazosin is an active R-enantiomer of Terazosin and a potent antagonist of α1-adrenoceptor [(α1a, α1b, and α1d-adrenoceptor] with Ki values of 6.51 nM, 1.01 nM, and 1.97 nM, respectively).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | In Stock | In Stock | |
| 2 mg | $58 | In Stock | In Stock | |
| 5 mg | $97 | In Stock | In Stock | |
| 10 mg | $148 | In Stock | In Stock | |
| 25 mg | $253 | In Stock | In Stock | |
| 50 mg | $371 | In Stock | In Stock | |
| 100 mg | $520 | - | In Stock | |
| 500 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $107 | In Stock | In Stock |
| Description | (R)-Terazosin is an active R-enantiomer of Terazosin and a potent antagonist of α1-adrenoceptor [(α1a, α1b, and α1d-adrenoceptor] with Ki values of 6.51 nM, 1.01 nM, and 1.97 nM, respectively). |
| Targets&IC50 | α1A-adrenoceptor:6.51 nM (Ki), α1D-adrenoceptor:1.97 nM (Ki), α1B-adrenoceptor:1.01 nM (Ki) |
| In vitro | (R)-Terazosin exhibits low affinity for α2a, α2B, and α2c-adrenoceptors (Ki of 3.85 μM, 0.33 μM, and 0.37 μM, respectively). It may serve as a useful probe for exploring the functional roles of adrenoceptor subtypes in various tissues. |
| In vivo | (R)-Terazosin demonstrates antagonism at rat atrial α2B receptor (pEC30: 5.69) and at rat vas deferens α1A and α2A receptors (pA2: 7.5 and 5.31, respectively). |
| Molecular Weight | 387.43 |
| Formula | C19H25N5O4 |
| Cas No. | 109351-34-0 |
| Smiles | COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |
| Relative Density. | 1.332 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (141.96 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.91 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.